Actively Recruiting
Plan of the Day Radiotherapy
Led by Oslo University Hospital · Updated on 2022-12-02
190
Participants Needed
1
Research Sites
528 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study objectives are to improve the treatment of LACC patients and to increase knowledge of the potential benefit of the plan-of-the-day concept on side effects during and after radiotherapy.
CONDITIONS
Official Title
Plan of the Day Radiotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed cervical cancer eligible for definitive radiochemotherapy
- FIGO stage IB1-IVa
- Over 18 years old
- Speaks and understands Norwegian or English
- ECOG performance status 0-2
- Histology of squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
- Ability to understand and complete patient questionnaires and willing to sign informed consent
- Large movers with fundus movement of at least 2.5 cm
You will not qualify if you...
- Evidence of distant metastasis (except suspicious paraaortic lymph nodes below renal vessels if covered by radiation)
- Previous surgery for cervical cancer
- Uncontrolled somatic illness
- Psychiatric illness or social situations limiting study compliance
- Prior pelvic radiotherapy
- Pregnant or breastfeeding
- Currently treated for other invasive cancers except non-melanoma skin cancers
- Presence of nephrostomy
- Inflammatory bowel disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Oslo University Hospital
Oslo, Norway, 0379
Actively Recruiting
Research Team
K
Kjersti Bruheim, MD PhD
CONTACT
I
Ingvild Deggerdal
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here